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The search for appropriate vaccine candidates and drug targets against onchocerciasis has so far been
confronted with several limitations due to the unavailability of biological material, appropriate molecular
resources, and knowledge of the parasite biology. To identify targets for vaccine or chemotherapy development
we have undertaken two approaches. First, cDNA expression libraries were constructed from life cycle stages
that are critical for establishment of Onchocerca volvulus infection, the third-stage larvae (L3) and the molting
L3. A gene discovery effort was then initiated by random expressed sequence tag analysis of 5,506 cDNA clones.
Cluster analyses showed that many of the transcripts were up-regulated and/or stage specific in either one or
both of the cDNA libraries when compared to the microfilariae, L2, and both adult stages of the parasite.
Homology searches against the GenBank database facilitated the identification of several genes of interest,
such as proteinases, proteinase inhibitors, antioxidant or detoxification enzymes, and neurotransmitter re-
ceptors, as well as structural and housekeeping genes. Other O. volvulus genes showed homology only to
predicted genes from the free-living nematode Caenorhabditis elegans or were entirely novel. Some of the novel
proteins contain potential secretory leaders. Secondly, by immunoscreening the molting L3 cDNA library with
a pool of human sera from putatively immune individuals, we identified six novel immunogenic proteins that
otherwise would not have been identified as potential vaccinogens using the gene discovery effort. This study
lays a solid foundation for a better understanding of the biology of O. volvulus as well as for the identification
of novel targets for filaricidal agents and/or vaccines against onchocerciasis based on immunological and
rational hypothesis-driven research.
Onchocerciasis, or river blindness, is the second leading
cause of infectious blindness in humans. According to the
World Health Organization, an estimated 18 million people
are infected with the parasite, with over 1 million at risk of
visual impairment (79). Ivermectin was shown to be both safe
and effective in the treatment of onchocerciasis and has be-
come the drug of choice for mass distribution (79). However,
ivermectin is only effective against microfilariae released into
the skin, and prolonged annual ivermectin therapy of up to 10
to 15 years is required for clearance of onchocerciasis from a
human population (63). The potential development of drug-
resistant strains of the parasite also demands the identification
of alternative drug candidates for onchocerciasis control (67).
The number of suitable targets for chemotherapy that have
been identified in filarial and other parasitic nematodes is low,
due in part to an inadequate understanding of the basic biology
of these parasites. Ivermectin, as well as the other commonly
used drugs, does not exploit known targets in the filarial par-
asites and was discovered by chance. Previous research has
centered on important metabolic processes such as energy
metabolism and nucleotide synthesis (75). However, nonmeta-
bolic processes are also important either for parasite survival
within the host or for propagation. Filarial nematodes do not
multiply in the definitive host but molt, grow, and mature for a
period following infection, after which they devote their energy
almost entirely to microfilaria production. None of the pro-
teins involved in these processes have yet been explored as
possible drug targets.
An additional tool in the control of onchocerciasis would be
the development of a prophylactic vaccine. One essential step
in the development of immunoprophylaxis is the identification
and immunochemical characterization of potential vaccine
candidates that play a role in stimulating protective host im-
munity. There is mounting evidence that naturally acquired
immunity against Onchocerca volvulus infection can occur in
humans (20). Additionally, work in animal models suggests
that the protective immune responses are directed at incoming
infective third-stage larvae (L3) (37, 45, 62, 72). Interestingly,
studies from animal models of filarial infections suggest that
protective immune responses may inhibit the growth, develop-
ment, and molting of the L3 to L4 (19, 37, 72). This suggests
that molting L3 (mL3) proteins as well as excretory-secretory
(ES) products are an important source of protective antigens
(19, 46). Serum samples from O. volvulus putatively immune
(PI) individuals and protected animals recognized similar an-
tigens present only in day 2 extracts and ES products of molt-
ing larvae (32).
Due to the paucity of parasite material, construction of
cDNA expression libraries and molecular cloning approaches
are important methods for isolating and characterizing pro-
tein antigens. Immunoscreening of cDNA libraries, constructed
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from adult worms (18) and more recently from L3 (SAW94WL-
OvL3), using polyclonal antibodies has resulted in the identi-
fication of more than 50 O. volvulus antigens (http://helios.bto
.ed.ac.uk/mbx/fgn/OnchoNet/onchotable1.html). About 10 of
the proteins are also present in larval stages of O. volvulus,
some of which have been shown to confer partial protection
against L3 challenge in surrogate rodent models of onchocer-
cal infections (34, 39, 70, 71). However, there is still a need for
the identification of novel larval proteins, particularly from the
mL3 stage, that may prove to be better candidates for protec-
tive immunity alone or in combination with other molecules.
In an attempt to identify, clone, and characterize novel drug
targets and vaccine candidates from the infective and molting
larval stages of O. volvulus, we developed a bipartite program.
(i) An expressed sequence tag (EST) project was undertaken
to survey gene expression in both L3 and mL3 stages of the
parasite life cycle. The thousands of new genes cloned in this
effort and their expression profiles have been used to identify
a set of potentially interesting vaccine and drug target candi-
dates. (ii) The mL3 cDNA expression library was screened
using a pool of sera from O. volvulus PI individuals. We de-
scribe the results of this effort, which has led to the identifica-
tion of potential targets for drug and vaccine development and
provided new information about genes that are highly ex-
pressed at these critical stages of the parasite life cycle.
MATERIALS AND METHODS
O. volvulus cDNA library construction. All parasite material was prepared in
the Tropical Medicine Research Station, Kumba, Cameroon. L3 were obtained
from flies 7 days after infection with skin microfilariae. To obtain molting larvae,
freshly dissected L3 were cultured in vitro in the presence of a 1:1 mixture of
Iscove’s modified Dulbecco’s medium and NCTC-135, 20% fetal calf serum, and
antibiotic-antimycotic solution (Life Technologies, Gaithersburg, Md.) for 3 days
at 37°C. Larvae were collected after 1, 2, or 3 days in culture, washed in Tris-
EDTA buffer and then snap-frozen in liquid nitrogen. Ultrastructural examina-
tion by electron microscopy confirmed that these cultured larvae had started the
molting process, as the separation between the cuticle of L3 and the newly
synthesized cuticle of L4 was evident in some of the cross sections (data not
shown).
Total RNA was isolated separately from 9,000 vector-derived L3 and 6,000
mL3. The mRNA from each parasite stage was fractionated using the MicroFast
Track mRNA isolation kit (Invitrogen, Carlsbad, Calif.) according to the man-
ufacturer’s instructions. Individual unidirectional cDNA libraries were con-
structed using the Lambda Uni-ZAP XR cDNA synthesis kit (Stratagene, La
Jolla, Calif.) according to the manufacturer’s instructions with the exception that
drop dialysis against double-distilled water was performed instead of ethanol
precipitation. Following ligation into the vector, the mixture was packaged using
Gigapak III Gold Packaging Extract (Stratagene). Dilutions of the primary
library were then plated out, and the titer and percentage of nonrecombinants
were determined. The L3 cDNA library (SAW94WL-OvL3) had 1.8 3 105
independent recombinants with an average insert size of 900 bp. The mL3 cDNA
library (SL96MLW-OvmL3) had 1.1 3 106 independent recombinants with an
average insert size of 1,200 bp.
PCR and sequence analysis of ESTs. Randomly selected individual plaques
from the L3 and mL3 cDNA libraries were transferred into 50 ml of SM buffer
(0.1 M NaCl, 50 mM Tris-HCl [pH 7.5], 8 mM MgCl2, 0.01% gelatin). To amplify
the individual cDNA inserts, PCR was carried out on 5-ml aliquots of each
plaque with T3 and T7 vector primers. Thirty cycles of amplification were per-
formed under the following conditions: 94°C for 30 s, 55°C for 30 s, and 72°C for
60 s. The PCR products were purified and then sequenced using the 59 SK vector
primer and a 9600 Thermal Cycler (PE Biosystems, Foster City, Calif.). Purified
sequencing reactions were resuspended in loading buffer and run on a 377
automated DNA sequencer (PE Biosystems). Sequences were edited to remove
the vector sequences and poly(A) tails, and 2,935 L3 and 2,571 mL3 EST
sequences were then submitted to the GenBank EST database.
Clustering and analysis of O. volvulus ESTs. All the sequences used in this
analysis are publicly available through the National Center for Biotechnology
Information dbEST (http://www.ncbi.nlm.nih.gov/irx/dbST/dbest_query.html) or
the nonredundant databases. Before clustering, clones representing rRNA or
contaminating Escherichia coli DNA were removed from the starting datasets by
BLASTN comparison against the fully sequenced Brugia malayi 18S, 28S rRNA
(M. L. Blaxter, personal communication) and the E. coli genome, respectively.
All clones with BLAST probability scores of e250 or less to either of these
datasets were eliminated from the subsequent analysis. EST clusters were then
generated using a process that incrementally compares EST sequences against a
local database using the BLASTN algorithm (1). If an EST did not match any
other sequence in the database with a BLASTN probability score of e250 or less,
it was then given a unique cluster number, beginning with OVC00001, and added
to the database. When an EST matched one or more ESTs already in the
database it was assigned to that corresponding cluster. If two or more clusters
had to be merged, the cluster with the lowest number took precedence. Each
cluster, along with its member ESTs and abundance profiles were exported into
a FileMaker Pro database (Filemaker, Inc., Santa Clara, Calif.) Consensus se-
quences for the clusters were generated using PHRAP (provided courtesy of P.
Green with minor modifications by S. J. Jones) or AssemblyAlign (Oxford Mo-
lecular, Oxford, United Kingdom). The major open reading frames for consensus
sequences were then predicted using MacVector (Oxford Molecular) and ana-
lyzed using PSORT (54) (http://psort.nibb.ac.jp/) to determine if the predicted
amino acid sequence contained a potential secretory leader (SECL1). In ad-
dition, ESTs or consensus sequences were used in BLASTX or TBLASTX
searches of Genpep (GenBank’s nonredundant protein database [http://www
.ncbi.nlm.nih.gov:80/blast]), wormpep19 (.19,000 genes predicted from the
Caenorhabditis elegans genome [http://www.sanger.ac.uk/Projects/C_elegans
/wormpep/]), and a database constructed from clustered ESTs sequenced from
the closely related lymphatic filarial nematode B. malayi to identify homology
with other known genes. Clusters representing genes that are possible drug
targets (such as proteinases and receptors) or otherwise interesting were iden-
tified using text-based searches of dbEST (http://www.ncbi.nlm.nih.gov/irx/dbST
/dbest_query.html).
Immunoscreening of the O. volvulus mL3 cDNA expression library using a
pool of sera from PI individuals. A pool of sera from individuals living in
Ecuador and Liberia who were identified and classified as putatively immune to
O. volvulus infection (29, 54) was used to immunoscreen 106 PFU of the ampli-
fied O. volvulus mL3 cDNA according to standard procedures. Prior to screening
the libraries, and in order to reduce redundancy, the serum pool was depleted of
antibodies by affinity chromatography against recombinant O. volvulus antigens
previously cloned and characterized in S. Lustigman’s laboratory. Recombinant
antigens which were isolated by immunoscreening of L3, L4, or adult female
cDNA libraries using rabbit anti-L3 and -L4 (Ov9M, Ov-10-1, and Ov6-5) or PI
sera from Liberia and Ecuador (Ov-CPI-2, Ov-GRP-1, Ov-RAL-2, Ov-API-1,
Ov-ALT-1, Ov-GBP-2, Ov-FBA-1, Ov-ASP-1, Ov-CPL-1, OvB8, OvB95, and
Ov103) were used for depletion as described (32). pBluescript plasmid DNA
from the mL3 immunoreactive clones was isolated by the rapid in vivo excision
protocol according to the manufacturer’s instructions (Stratagene). Plasmid DNA
was then purified using the Concert Rapid Plasmid Purification System (Life Tech-
nologies). Nucleotide sequences were obtained using an ABI 373XL sequencer
(PE Biosystems). Sequence analysis was performed using the Vector NTI Suite
(Informax Inc., Bethesda, Md.) software and World Wide Web interface.
Expression of recombinant proteins. The open reading frames of the cDNA
clones isolated by immunoscreening were inserted into the multiple-cloning site
of the pProEX HT expression vector (Life Technologies), designed for the
expression of hexahistidine-tagged fusion proteins in E. coli DH5a. Following
induction with 1 mM IPTG (isopropyl-b-D-thiogalactopyranoside), bacterial cells
were harvested and lysed in B-PER reagent (Pierce, Rockford, Ill.). Both soluble
and insoluble E. coli fractions were tested for the presence of corresponding
recombinant protein by Western blot analysis using the India HisProbe-HRP kit
(Pierce). Recombinant proteins were purified either under nondenaturing con-
ditions using the Xpress System Protein Purification (Invitrogen), or by prepar-
ative sodium dodecyl sulfate-polyacrylamide gel electrophoresis using the Prep-
Cell (Bio-Rad, Hercules, Calif.) according to manufacturers’ instructions.
ELISA. Individual human serum samples from subjects living in the onchocer-
ciasis endemic region of Kumba, Cameroon, were analyzed for reactivity with
recombinant antigens by enzyme-linked immunosorbent assay (ELISA). Subjects
who were positive for microfilariae in skin biopsies, with symptomatic or non-
symptomatic infections, and had never been previously treated for onchocerciasis
were categorized as infected individuals (INF) (n 5 21). Individuals who were
negative for skin microfilariae, with no clinical history of infection, and who were
negative in a PCR-based assay for an O. volvulus specific tandem repeat DNA in
their skin biopsies (83) were classified as PI (n 5 21) (74). ELISA was performed
as described (36) using 50 to 100 ng of purified recombinant protein per well and
a serum dilution of 1:200. The serum samples were blocked with E. coli extract
(400 mg/ml; Promega, Madison, Wis.) prior to incubation with the antigen.
Bound antibodies were detected by reaction with a 1:3,000 dilution of horserad-
ish peroxidase-conjugated goat anti-human immunoglobulin G (IgG) (Zymed,
San Francisco, Calif.) and 3,39,5,59-tetramethylbenzidine substrate (Sigma, St.
Louis, Mo.). Absorbance was measured at 450 nm (SpectraMax 190 ELISA
Reader; Molecular Devices, Sunnyvale, Calif.). The control sera used were from
healthy New York resident blood donors. Differences in the immunoglobulin
levels between groups were compared using the two-tailed non-parametric
Mann-Whitney U test. Results were considered statistically significant if the P
value was less than 0.05.
RESULTS
Characteristics of the O. volvulus cDNA libraries. After fil-
tering for contaminating rRNA and E. coli sequences, analysis
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of 2,554 ESTs from the L3 cDNA library showed that 28%
were novel to the public databases, 64% had significant simi-
larity to proteins in GenBank, and 57% had significant simi-
larity to ESTs sequenced from the lymphatic filarial nematode
B. malayi. Of the ESTs, 40% had significant similarities to
proteins in wormpep19 (.19,000 proteins predicted from the
C. elegans genome), and 7% had similarities only to proteins in
wormpep19. Analysis of 2,081 EST sequences from the mL3
cDNA library showed that 26% were novel to public databases,
63% had significant similarity to proteins in GenBank, and
56% had significant similarity to ESTs sequenced from B.
malayi. 55% of the ESTs had significant similarities to proteins
in wormpep19, and 11% had similarities only to proteins in
wormpep19.
Gene expression profiles in O. volvulus L3 and mL3 larvae.
Analysis of the clustered O. volvulus ESTs and cross-compar-
ison of the ESTs from the L3 and mL3 libraries revealed a
differential distribution of ESTs in both datasets, as summa-
rized in Table 1. We found genes within the present O. volvulus
database that are differentially expressed and/or up-regulated
in the L3 and mL3 stages relative to other larval (microfilaria
and L2) and adult stages. Some of these genes encode previ-
ously characterized structural and housekeeping proteins
found in all metazoans, such as actin, 26S proteasome subunits,
and histones. Others are active components in the metabolism
of the parasite such as glyceraldehyde-3-phosphate dehydro-
genase and fructose-bisphosphate aldolase. Although these
genes are not expected to be stage specific, the high metabolic
activity of the L3 and mL3 may require their up-regulation
during these stages of development relative to the adult stages.
Several up-regulated genes in L3 and/or mL3 were previously
characterized as antigens such as Ov-RAL-2, OvL3-1, beta-
galactoside-binding lectin, and onchocystatin (7, 41, 47, 56).
The biological or immunological functions of these genes in
the parasite-host relationship have been the subject of much
discussion. However, their high representation in these data-
sets supports the overall hypothesis that they are playing an
important role in some aspect of the biology of L3 and/or mL3,
such as adaptation to the host environment. The other L3
and/or mL3 up-regulated clusters represent genes that have
not been characterized in filariae and many are either com-
pletely novel or only have similarity to genes predicted in the
C. elegans genome (11).
Two of the most highly expressed genes in the L3 (in clusters
OVC00048 and OVC00109) are homologues of the B. malayi
abundant larval transcripts (Bm-alt-1 and Bm-alt-2) and the
18-kDa antigen of Dirofilaria immitis and Acanthocheilonema
viteae (23, 25, 61). The more abundant of these genes, in
cluster OVC00048, encodes the two O. volvulus antigens Ov-
ALT-1 and Ov-ALT-2 (39). Although the gene of the cluster
OVC00109 is related to Bm-alt-2 it is a novel member of this
family that has not yet been characterized. The function of
these gene products is unknown. The D. immitis alt-1 gene
(Di-alt-1) has been shown to be an ES component that may
also be expressed on the surface of the mL3 (23). Families of
other alt-like genes have been found in B. malayi and O. vol-
vulus, most of which are specifically expressed in only the L3 or
mL3. The cluster OVC00025 derives from an unrelated abun-
dant larval transcript gene family encoding the Ov-B66 antigen
(GenBank accession number AAB69626) which we previously
cloned from the L3 cDNA library by immunoscreening with PI
sera. A set of Brugia homologues was identified as differentially
expressed vector-derived L3 genes (Bm-alt-3 and Bm-alt-4) (5;
W. F. Gregory, personal communication). They are unrelated
to the Bm-alt-1 and Bm-alt-2 and thus were renamed agy-1 and
agy-2 (for abundant glycine- and tyrosine-rich proteins) based
on their amino acid composition. In both species these genes
appear to be expressed in a stage-specific manner, being abun-
dant transcripts in the L3 and mL3 with expression ending
before the completion of the L3-L4 molt (25).
The cluster OVC00237 derives from a gene family that was
also recently cloned and whose products were identified as
antigens in O. volvulus and B. malayi. It belongs to a nematode
gene family initially identified in Ancylostoma as a component
of secretions of activated L3 larvae called ancylostoma se-
creted protein (ASP) (41, 42) and another hookworm glyco-
protein called neutrophil inhibition factor (NIF) which binds
to the CD11b/CD18 receptor (53). Recent surveys of gene
expression in Necator americanus adults and Toxocara canis
infective L3 identified a dozen additional redundant ASP-like
genes (15, 73). Comparison with the recently completed C.
elegans genome revealed that it also possesses a large family of
these genes (11, 15). The ASPs are related to a number of
other vertebrate and invertebrate proteins, including helother-
mine venom proteins from lizards, sperm and testis proteins
from mammals, pathogenesis-associated proteins from plants,
and venom allergen antigen 5 from insects (27, 28). We have
identified three different ASP-like proteins within the On-
chocerca EST datasets (designated Ov-ASP, for activation-as-
sociated secreted protein), one of which we had previously
isolated by immunoscreening of the L3 cDNA expression library
(OvB93-RP [GenBank accession number AAB69625]). The ex-
pression profiles of these genes in B. malayi, T. canis, and
hookworms indicate that this protein family may be important
in establishing and maintaining infection in the mammalian
hosts (15, 73).
Structural components of the cuticle are also abundantly
expressed in L3 and mL3 relative to other larval and adult
stages. This was not unexpected, as waves of collagen synthesis
have been shown to precede each molt in C. elegans (38).
Eleven of the abundant L3 and mL3 clusters represent distinct
collagen genes. Six of these genes have differential expression
profiles found only in either the L3 or the mL3 EST dataset.
Some of these collagen genes may be specific components of
the L4 cuticle, as they have not been seen in our other larval or
adult datasets. Interestingly, the cuticlin and osteonectin-like
genes are restricted to the mL3 dataset, indicating that they
may be utilized later in the formation of the L4 cuticle than
some of the collagens that are synthesized in the infective L3.
A variety of enzymes are also involved in the processing, re-
modeling, and cross-linking of these cuticle components, and
they represent extremely attractive drug targets because of
their central role in parasite development (48, 59). Very few of
these proteins that are potentially involved in molting have
been cloned or characterized. Cysteine proteinases have been
implicated in the O. volvulus L3-to-L4 molting process (49).
One of the most abundantly expressed proteins in the L3
dataset is a cathepsin L-like cysteine proteinase. Its role in the
molting process and parasite transition from the vector to the
mammalian host is currently under investigation (D. B. Guil-
iano, J. McKerrow, X. Hong, and S. Lustigman, personal com-
munication).
Nine of the abundant gene clusters have significant hits only
to anonymous predicted genes from C. elegans (11). Two of
these abundant gene clusters, OVC00650 (EF hand calcium-
binding domains) and OV00667 (LIM metal binding domains),
have matches to short functional domains that may indicate
their potential function. Three others have SECL1s and thus
could be novel secretory products that are involved in the
molting process. The cluster OVC00480 appears to be ex-
pressed in only the mL3. C. elegans is a very tractable model
system which could be exploited as a tool to study the biolog-
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TABLE 1. Stage-specific or up-regulated genes in the L3 and mL3 EST datasetsa
Categoryg Clusterb Representative EST
Cluster profile
Homology(ies)
Ac Bd Ce Df
UR or PSS (L3) OVC00048 SWOvL3CAN54C08SK 358 5.70 317 20 18-kDa larval antigen, Ov64, Ov-alt-1, Ov-alt-2
OVC00142 SWOvL3CAN54A03SK 70 1.11 59 9 Onchocystatin, OvMBP/10, Ov7, Ov-cpi-2
OVC00237 SWOvL3CAN54C06SK 51 0.81 50 1 Venom allergen antigen homologue, B93-RP, Ov-asp-1
OVC00109 SWOvL3CAN52G06SK 27 0.43 27 0 Bm-alt-2 (B. malayi)
OVC00092 SWOvL3CAN60A11SK 25 0.39 25 0 Novel (SECL1)
OVC00762 SWOvL3CAN62B11SK 20 0.31 17 3 Cuticular collagen, Bm-col-2 (B. malayi)
OVC00099 SWOvL3CAN29A04SK 17 0.27 16 1 Troponin (B. malayi)
OVC00339 SWOvL3CAN28B11SK 17 0.27 15 2 Troponin, F42E11.4 (C. elegans)
OVC00916 SWOvL3CAN54F09SK 16 0.25 16 0 Cathepsin L-cysteine proteinase, Ov-cpl-1
OVC00079 SWOvL3CAN62C06SK 13 0.20 11 1 Similar to M02D8.1 (C. elegans)
OVC00634 SWOvL3CAN46D10 10 0.15 8 2 Globin (C. briggsae)
OVC00496 SWOvL3CAN50E11SK 9 0.14 8 0 Beta-galactoside-binding lectin, Ov-gbp-1
OVC00072 SWOvL3CAN45D10 8 0.12 5 1 Fructose-bisphosphate aldolase, Ov-fba
OVC00485 SWOvL3CAN57E02SK 7 0.11 7 0 Actin 1, Ov-act-1
OVC00704 SWOvL3CAN01D09SK 7 0.11 7 0 LIM domain protein, OvL3-1
OVC01107 SWOvL3CAN02H03SK 7 0.11 5 1 Novel
OVC00129 SWOvL3CAN61B04SK 6 0.09 6 0 Novel
OVC00469 SWOvL3CAN50A03SK 6 0.09 5 1 26S subunit S12
OVC00712 SWOvL3CAN60A04SK 6 0.09 5 1 Novel
OVC00380 SWOvL3CAN01H08SK 5 0.08 5 0 Cuticle collagen, F08G5.4 (C. elegans)
OVC00707 SWOvL3CAN52D10SK 5 0.08 4 1 Novel protein recognized by PI serum (SECL1)
OVC00807 SWOvL3CAN62A04SK 5 0.08 5 0 Cuticular collagen, Bm-col-2 (B. malayi)
OVC00951 SWOvL3CAN53C03SK 5 0.08 4 1 Peptidylglycine alpha-hydroxylating monooxygenase
(Drosophila melanogaster)
OVC01003 SWOvL3CAN51H08SK 5 0.08 5 0 Novel
OVC01239 SWOvL3CA721SK 5 0.08 4 1 Novel (SECL1) G-, F-, P-, and Y-rich protein
UR or PSS (mL3) OVC00032 SWOv3MCA1365SK 85 1.35 6 79 Cuticle collagen, F58F6.1 (C. elegans)
OVC00144 SWOv3MCA756SK 29 0.46 2 26 Cuticle collagen, R09A8.4 (C. elegans)
OVC00017 SWOv3MCA025SK 22 0.35 0 19 Small serine proteinase inhibitor, Ov-spi-1
OVC00246 SWOv3MCA2020SK 22 0.35 0 22 CUT-1 cuticlin (Ascaris lumbricoides)
OVC00156 SWOv3MCAM01G07SK 12 0.19 0 12 Novel (SECL1)
OVC00572 SWOv3MCAM03A04 12 0.19 0 11 Novel (SECL1)
OVC00441 SWOv3MCA1532SK 9 0.14 0 9 CUT-1-like cuticlin (A. lumbricoides)
OVC00130 SWOv3MCAM07F08SK 7 0.11 0 7 Novel (SECL1)
OVC00510 SWOv3MCA1970SK 7 0.11 0 7 Ostionectin-like protein, Ov-ost-1 (C. elegans)
OVC00699 SWOv3MCAM11G07SK 6 0.09 0 6 Cuticle collagen, F17C8.2 (C. elegans)
OVC00322 SWOv3MCA717SK 5 0.08 0 5 Cystathionine gamma-lyase, F22B8.6 (C. elegans)
OVC00364 SWOv3MCAM02A11SK 5 0.08 1 4 SAR1 RAS-related protein, ZK180.4 (C. elegans)
OVC00465 SWOv3MCA218SK 5 0.08 1 4 Tumor protein homologue, Bm-tph-1 (B. malayi)
OVC00480 SWOv3MCA622SK 5 0.08 0 5 Neuromodulin-like, ZK1290.8 (C. elegans) (SECL1)
OVC00811 SWOv3MCA135SK 5 0.08 1 4 Similar to T27C4.1 (C. elegans)
UR (L3, mL3) OVC00039 SWOvL3CAN03H02SK 133 2.12 89 37 Cuticle collagen col-34, F36A4.10 (C. elegans)
OVC00025 SWOvL3CAN05H09SK 76 1.21 32 44 L3 larval antigen B66-RP, Ov-agy-1, Ov-agy-2
OVC00036 SWOvL3CA252SK 65 1.03 29 35 Cuticle collagen, ZC373.7 (C. elegans)
OVC00084 SWOv3MCA249SK 25 0.39 13 10 Glyceraldehyde-3-phosphate dehydrogenase, Ov-gpd-1
OVC00082 SWOv3MCA1047SK 23 0.36 16 6 Actin-1A, Ov-act-1a
OVC00505 SWOv3MCAM03H10 18 0.28 8 10 Galectin-3 (laminin-binding protein), Ov87, Ov-gbp-2
OVC00411 SWOvL3CAN09D04 16 0.25 4 12 Heat shock protein 12.6, C14B9.1 (C. elegans)
OVC00482 SWOv3MCA1520SK 16 0.25 9 6 Novel (SECL1)
OVC00332 SWOvL3CAN14G06 13 0.20 9 2 Glutamic-rich protein, F53A9.10 (C. elegans)
OVC00413 SWOvL3CAN18A04 11 0.17 4 7 Similar to R07E5.13 (C. elegans)
OVC00461 SWOvL3CAN53A07SK 11 0.17 6 3 Hypodermal antigen, Ov17, Ov-ral-2
OVC00238 SWOvL3CAN10G08 10 0.15 7 3 Cuticle collagen 2(F) (B. pahangi)
OVC00295 SWOvL3CAN58B02SK 9 0.14 7 2 Novel
OVC00340 SWOvL3CAN09C03 9 0.14 5 4 Histone H3.3, F45E1.6 (C. elegans)
OVC00650 SWOv3MCAM03G02 9 0.14 4 4 EF-hand calcium binding protein, F43C9.2 (C. elegans)
OVC00667 SWOvL3CAN11E10 9 0.14 7 2 Two LIM-like binding domains, T04C9.4 (C. elegans)
OVC00005 SWOv3MCA003SK 8 0.12 2 6 Similar to aquaporin-1 Tc-aqp-1 (T. canis)
OVC00028 SWOvL3CAN45D05 8 0.12 3 4 Transthyretin-like family, Y5F2A.1 (C. elegans) (SECL1)
OVC00037 SWOvL3CAN12B09 8 0.12 3 4 Similar to C34E7.4 (C. elegans) (SECL1)
OVC00171 SWOvL3CA1139SK 8 0.12 3 4 GST 2 (PI class) Ov-gst-2
OVC00291 SWOvL3CAN50H05SK 7 0.11 4 3 Cuticular collagen, F17C8.2 (C. elegans)
OVC00106 SWOvL3CAN63C12SK 7 0.11 5 2 ATP synthase complex f subunit-like protein (C. elegans)
OVC00432 SWOvL3CAN06B08SK 7 0.11 4 3 Similar to C16C10.11 (C. elegans)
OVC00103 SWOv3MCA057SK 5 0.08 2 3 Cuticular collagen, T28C6.4 (C. elegans)
OVC00793 SWOvL3CA309SK 5 0.08 3 2 Similar to C53A5.1 (C. elegans) (SECL1)
a Of the 4,635 L3 and mL3 ESTs, 2.4% (corresponding to 111 individual ESTs grouped in 10 clusters) are L3 specific and 2.2% (corresponding to 103 ESTs in 10
clusters) are mL3 specific, while 25% (corresponding to 1,164 ESTs in 45 clusters) are present in both L3 and mL3 EST datasets.
b Each cluster has at least five individual ESTs, .85% of which have been sequenced from the L3-mL3 datasets with the remaining 15% being ESTs from other stages
(microfilariae, L2, and adult male and female).
c Total number of ESTs within the cluster.
d Percentage of the O. volvulus ESTs in the dataset.
e Number of ESTs from the L3 dataset in the cluster.
f Number of ESTs from the mL3 dataset in the cluster.
g UR or PSS (L3), up-regulated or potentially stage-specific genes expressed in the L3; UR or PSS (mL3), up-regulated or potentially stage-specific genes expressed
in mL3; UR (L3, mL3), up-regulated genes expressed in the L3 and mL3.
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ical functions of such proteins that may represent novel nem-
atode-specific gene families (8). Twelve of the abundant gene
clusters in both L3 and mL3 datasets were completely novel,
with no significant similarity to any protein in the GenBank
database, and thus are possibly novel parasite-specific mole-
cules. The predicted open reading frames of six of these clus-
ters also have SECL1s.
Genes of interest identified by the EST initiative. Not all
genes that are attractive for vaccine or drug development are
stage specific or produce abundant transcripts. If a particular
gene or class of genes is believed to be an appropriate target
based on studies done in other systems, their homologues in
O. volvulus can be identified within the EST dataset (including
the approximately 2,000 clusters that have only one EST) (Ta-
ble 2). The categories of genes listed below encode proteins
that are important for the development and survival of the
parasite within the host. Not surprisingly, we were also able to
identify ESTs corresponding to several immunodominant pro-
teins that had previously been cloned from other O. volvulus
cDNA expression libraries by immunoscreening (http://helios
.bto.ed.ac.uk/mbx/fgn/OnchoNet/onchotable1.html), some of
which are also being pursued for diagnostic and vaccine devel-
opment purposes.
(i) Genes involved in the regulation of the immune response.
In surveying the ESTs from the L3 and mL3 cDNA libraries,
we have been able to identify several genes whose products
show similarity to proteins utilized by the immune system and
thus may be involved in the manipulation of host immune
responses. These include two homologues of macrophage mi-
gration inhibitory factor, O. volvulus mif-1 and mif-2 (Ov-mif-1
and Ov-mif-2). The Brugia homologue of Ov-mif-1 has been
shown to be secreted and have a cytokine-like activity (60), but
its exact role in the manipulation of the immune response is
still unknown. Galectins are beta-galactoside-binding lectins
found in a variety of organisms, including nematodes. A galec-
tin (Ov-gbp-2) that had been previously isolated by immuno-
screening of the O. volvulus L3 library with PI sera (40) was
identified in our EST survey and found to be up-regulated (18
ESTs and in L3 and mL3 stages only). Another galectin (Ov-
gbp-1) which had been previously isolated by immunoscreening
of an O. volvulus adult female cDNA library using loiasis pa-
tient sera was shown to specifically bind IgE (and not IgG) in
a lactose-inhibitable manner, suggesting its role in the patho-
physiology of filarial infections (41).
(ii) Proteinases. Proteolytic enzymes have been identified as
drug targets and vaccine candidates in a variety of disease
systems. Three different putative proteinase genes have been
identified from the L3 and mL3 EST sequences. The highly
expressed Ov-cpl-1 (16 ESTs in L3 only) shows high homology
to cathepsin L-like enzymes, whereas the Ov-cpb-1 is similar to
a large family of C. elegans cathepsin B-like enzymes. Cathep-
sin L-like enzymes have been isolated from a variety of nem-
atodes, including C. elegans, D. immitis, Haemonchus contortus,
T. canis, and Ancylostoma caninum. The D. immitis, Brugia
pahangi, and O. volvulus cathepsins have been shown to play a
vital role in molting (Guiliano et al., unpublished data). The
third proteinase identified, encoded by a gene of cluster
OVC00100, is similar to a large family of astacin-like metallo-
proteinases from C. elegans with tsp (thrombospondin and pro-
perdin)-like repeats. Metalloproteinases have been shown to
be involved in molting in some nematodes. A 44-kDa zinc-
metalloprotease in H. contortus was shown to be responsible
for the digestion of the ring region of the L2 cuticle before
molting (24). D. immitis and B. pahangi metallopeptidases were
also shown to be intimately associated with molting as well as
activities that might facilitate larval migration (31, 64).
(iii) Proteinase inhibitors. Specific protein inhibitors of pro-
teinases have been isolated from filarial nematodes and were
suggested to play a role in the inhibition of enzymes secreted
from host immune cells (81, 82), blocking of antigen processing
(W. F. Gregory, personal communication) and control of en-
dogenous proteinases involved in parasite development (47).
We identified five proteinase inhibitors in the L3 and mL3 EST
datasets. Two are cystatin-like cysteine proteinase inhibitors
(encoded by Ov-cpi-1 and Ov-cpi-2). The Ov-cpi-2 gene prod-
uct was originally cloned as an antigen, onchocystatin, from O.
volvulus (47) and has also been recently characterized in B.
malayi (25) and A. viteae (26). While Ov-cpi-2 is transcribed
throughout the parasite life cycle, it is clearly up-regulated in
O. volvulus L3 (59 ESTs out of 70 are only in L3 [Tables 1 and
2]), where it was proposed to play a role in molting (47). The
B. malayi cpi-2 is present in the ES products of larval and adult
parasites, and the recombinant protein inhibits antigen pro-
cessing (W. F. Gregory, personal communication), while Av17
was shown to directly inhibit T-cell proliferation (26). The
serine proteinase inhibitor (Ov-spn-1) of the serpin family has
a homologue in B. malayi (Bm-spn-1) that was shown to be
highly expressed in L3 but not in L4 or adults and to be present
in the ES products, where it is believed to interact with serum
proteins (81). The second serine proteinase inhibitor (Ov-
spi-1) belongs to a novel family of low-molecular-weight inhib-
itors originally isolated from Ascaris suum (3), where they are
thought to be involved in protecting the nematodes from host
trypsin and chymotrypsin activities. The Ov-spi-1 gene appears
to be up-regulated in the mL3 (19 ESTs out of 22), and its
function in O. volvulus is currently under investigation (D.
Guiliano and S. Lustigman, unpublished data). Other mem-
bers of this family have recently been identified in Anisakis
simplex and A. suum (55) as well as in the C. elegans genome
(11). An up-regulated aspartyl protease inhibitor (Ov-api-1) in
mL3 was previously characterized as an immunodominant an-
tigen (Ov33) in O. volvulus (77). Ov-spi-1 and Ov-api-1 genes
code for part of a family of proteinase inhibitors originally
characterized from Ascaris and which has not been seen out-
side of the phylum Nematoda (3, 51). These inhibitors could
support the identification of synthetic molecules to specifically
inhibit the endogenous or exogenous corresponding enzymes,
and thus interfere with the function of these molecules during
development in the host.
(iv) Antioxidant and detoxification enzymes. Several genes
encoding antioxidant and detoxification enzymes (three super-
oxide dismutases [SOD], two glutathione-S-transferases [GST],
and two thioredoxin peroxidases [TPX]) have already been
cloned using PCR approaches and are well characterized in O.
volvulus (69). All of these genes are represented in the L3 and
mL3 EST datasets, of which Ov-tpx-2, Ov-sod-1, and Ov-sod-2
are abundantly expressed in both L3 and mL3 (82, 18, and 14
ESTs, respectively). These antioxidant and detoxification en-
zymes are believed to play a role in protecting the nematodes
from host immune effector mechanisms and are being pursued
as drug targets (69).
(v) Nuclear hormone receptors. Nuclear hormone receptors
have been implicated in several important aspects of nematode
biology, including sex determination (9), dauer formation
(2), molting (44), and early development and reproductive
functions (80). Human hormone receptors have been targets
of rational drug design programs which aim to develop com-
pounds that can control hormone receptor activity (52). The
Macrofil Chemotherapy Project of the World Health Organi-
zation has identified nematode nuclear hormone receptor re-
ceptors as potential drug targets and is interested in developing
reagents that will interfere with their function. Two nuclear
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TABLE 2. Genes of potential interest identified by the EST initiative




OVC01428 SWOvL3CAN61D08SK Ov-mif-1 9 2/0 Macrophage migration inhibitory
factor homologue (B. malayi)
OVC00958 SWOvL3CA187SK Ov-mif-2 1 1/0 Macrophage migration inhibitory
factor homologue, C52E4.2
(C. elegans)
OVC00496 SWOvL3CAN50E11SK Ov-gbp-1 9 8/0 Beta-galactoside-binding lectin
OVC00505 SWOv3MCAM03H10 Ov-gbp-2 18 8/10 Galectin binding protein, Ov87
Proteinases OVC00916 SWOvL3CAN54F09SK Ov-cpl-1 16 16/0 Cathepsin L (D. immitis and
B. pahangi)
OVC02102 SWOv3MCAM03H03 Ov-cpb-1 1 0/1 Cathepsin B, F26E4.3 (C. elegans)
OVC01179 SWOvL3CA420SK 2 2/0 Metalloproteinase with TSP-like
repeats, R151.5 (C. elegans)
Proteinase inhibitors OVC00784 SWOv3MCA640SK Ov-spn-1 3 3/0 Serpin (serine proteinase inhibitor)
(B. malayi)
OVC00017 SWOv3MCA025SK Ov-spi-1 22 0/19 Small serine proteinase inhibitors
(A. suum)
OVC00142 SWOvL3CAN54A03SK Ov-cpi-2 70 59/9 Onchocystatin, Ov7
OVC01075 SWOvL3CAN12H04 Ov-cpi-1 4 4/0 Cystatin homologue (B. malayi)




OVC00018 SWOvL3CAN38F12 Ov-tpx-2 93 39/43 TPX
OVC00419 SWOv3MCA780SK Ov-tpx-3 8 2/4 TPX
OVC01115 SWOv3MCAM02B04SK Ov-gst-1 5 0/3 GST 1
OVC00171 SWOvL3CA1139SK Ov-gst-2 8 3/4 GST 2
OVC00056 SWOvL3CAN12H07 Ov-sod-1 22 12/6 Cytoplasmic SOD (Cu/Zn)
OVC02959 SWOvL3CA395SK Ov-sod-2 14 9/5 Secreted SOD (Cu/Zn)
OVC01526 SWOv3MCA2030SK Ov-sod-3 1 0/1 SOD (Mn)
OVC00681 SWOvL3CAN01A05SK Ov-lgl-1 2 2/0 Lactolyglutathione lyase
Nuclear hormone
receptors
OVC00074 SWOv3MCA2080SK 3 1/1 Steroid-thyroid-retinoic nuclear
hormone receptor, F33D4.1
(C. elegans)




OVC00899 SWOvL3CAN61H03SK 2 1/1 Acetylcholine receptor alpha-7
chain, C33G3.3 (C. elegans)
OVC00451 SWOv3MCA1116SK 1 0/1 Ligand-gated ionic channel, T21F2.1
(C. elegans)
OVC01287 SWOv3MCA1813SK 1 0/1 GABA and glycine receptors,
C27H5.5 (C. elegans)
OVC01230 SWOv3MCA175SK 1 0/1 Ionotropic GABA receptor subunit,
UNC-49B.1 (C. elegans)
Developmental genes OVC01723 SWOvL3CAN12G11 Ov-mom-5 1 1/0 Secreted frizzled related protein
sFRP-2, T23D8.1, mom-5
(C. elegans)
OVC00701 SWOv3MCA127SK Ov-sma-2 1 0/1 MAD protein, SMA-2, dwarfin
(C. elegans)
OVC00763 SWOv3MCA131SK 1 0/1 Quiescin, bone-derived growth
factor, F47B7.2 (C. elegans)
Cyclophilins OVC00488 SWOv3MCA625SK Ov-cyp-5 3 0/3 Cyclophilin isoform 5 (C. elegans)
OVC01004 SWOv3MCA1486SK Ov-cyp-10 1 0/1 Cyclophilin isoform 10 (C. elegans)
OVC00001 SWOv3MCA002SK Ov-cyp-4 1 0/1 Cyclophilin 4
OVC01099 SWOvL3CAN53F06SK Ov-cyp-2 1 1/0 Cyclophilin 2 (O. volvulus) and
cyclophilin isoform 3 (cyp-3)
(C. elegans)
OVC01257 SWOv3MCAM04F09SK 3 1/1 Cyclophilin-33B (Homo sapiens) and
Y116A8.34 (C. elegans)
a Total numbers of ESTs.
b Individual representations of ESTs in the L3 and mL3 datasets.
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hormone receptors have been identified in the L3 and mL3
EST datasets, potential steroid-thyroid-retinoic and thyro-
tropin receptors. Both have putative orthologues in C. elegans,
which could be then used as a model system to help determine
their function during development of the nematode and test
possible antagonists (43).
(vi) Neurotransmitter receptors. Drugs such as avermectin
and levamisole that interfere with neurotransmitter recep-
tors are already used as nematicides, making them attractive
for developing novel chemotherapeutic agents. Although not
abundant, four distinct potential neurotransmitter receptors
have been identified in the L3 and mL3 EST datasets (acetyl-
choline, ligand-gated ionic channel, GABA-glycine, and iono-
tropic GABA receptors). All of these have homologues or
orthologues in C. elegans. Only OVC01230, which is a subunit
of ionotrophic GABA receptor UNC-49, has a characterized
C. elegans mutant, with an uncoordinated phenotype (4).
(vii) Developmental genes. Single ESTs in the L3 and mL3
datasets have been identified which encode proteins whose
homologues are involved in C. elegans early development.
OVC01723 is related to C. elegans mom-5, a secreted frizzled
protein which is part of the wnt signaling pathway and controls
cell fate in the developing embryo (66). The OVC00701 gene
cluster is a homologue of C. elegans sma-2, a member of the
dwarfin family of proteins, which are part of a transforming
growth factor b signal transduction pathway (68). Because of
the experimental limitations in the manipulation of parasitic
nematodes, there have been very few studies investigating their
developmental biology at the molecular level. C. elegans as a
model metazoan and nematode can offer insights into nema-
tode developmental biology and thus new opportunities in the
discovery of strategies of interrupting the parasite life cycle.
(viii) Cyclophilins. Cyclophilins are a diverse group of pro-
teins that were originally characterized because they were the
target of the immunosuppressive drug cyclosporin A. Five dis-
tinct cyclophilins were identified in the L3 and mL3 EST data-
sets, all having orthologues in C. elegans. In filariae, several
cyclophilins and their cyclosporin sensitivities have been de-
scribed (50, 57). Three of the onchocerca cyclophilins have
not been previously characterized in filariae (those in clus-
ters OVC00488, OVC01004, and OVC01257). Cyclophilins
are currently being pursued as targets for novel anthelminthics
(13, 14). In nematodes, cyclophilins have also been implicated
in the processing of cuticle components (57, 58) and are there-
fore important for the development of the parasite in the host.
Isolation of immunoreactive clones from the O. volvulus mL3
cDNA library. Eight distinct genes were isolated by immuno-
screening with depleted PI sera, two of which had been previ-
ously isolated in other laboratories: the O. volvulus repetitive
antigen (10) and the intermediate filament antigen (12). Fol-
lowing GenBank database similarity searches, the other six
proteins were classified as either novel O. volvulus proteins
with similarity to other known proteins (to dynein [Ov-DLC-1],
calcium-binding protein [Ov-CBP-1], and guanosine 59-mono-
phosphate oxidoreductase [Ov-GMR-1]) or as novel O. vol-
vulus proteins with no similarity to other known proteins,
designated novel immunogenic proteins (NIP) (Ov-NIP-1,
Ov-NIP-2, and Ov-NIP-3). Without the immunoscreening
results, none of these antigens would have been selected for
immunological studies since they all appear to be rare tran-
scripts as depicted by their corresponding representation in the
EST datasets (0 to 2 ESTs). Additionally, some are conserved
and ubiquitous proteins and three of them are completely
novel.
(i) Novel O. volvulus immunogenic proteins with similarity
to known proteins. The Ov-dlc-1 cDNA (GenBank accession
number AF153718) encodes a 9.3-kDa protein that shows ex-
tensive similarity to the cytoplasmic dynein light chain (DLC)
(47). Dyneins are highly conserved proteins involved in various
types of microtubule-based intracellular transport and motility
and also in changing or maintaining the spatial distribution of
the cytoskeletal structure (6). A comparison of Ov-DLC-1 with
other DLCs shows 75% identity with Schistosoma mansoni
DLC-1 (30), 73% identity with the S. mansoni DLC-2 (42),
94% identity with human DLC (17), 99% identity with a pre-
dicted C. elegans DLC (GenBank accession number Q22799),
and 100% identity with B. malayi DLC (GenBank accession
number AA542793). Despite the high degree of identity be-
tween the parasite and the human primary amino acid se-
quences (73%), the S. mansoni DLC (Sm-DLC-2, Sm10) was
described as a T-cell-stimulating antigen associated with pro-
tective immunity in humans (42). Dynein and other structural
housekeeping genes such as calponin, tropomyosin, and para-
myosin have also been demonstrated to be of immunological
importance in onchocerciasis (33, 35, 71). No EST correspond-
ing to Ov-dlc-1 was found in the present O. volvulus EST data-
base (9,000 ESTs as of February 2000).
The Ov-cbp-1 cDNA (GenBank accession number AF153720
[OVC02120]) encodes a 62-kDa protein with seven classical
EF-hand calcium-binding domains. This protein does not show
significant similarity to previously described EF-hand calcium-
binding proteins present in the database and may represent a
novel member of this family. Interestingly, Ov-CBP-1 shows
60% identity to a predicted C. elegans calcium-binding protein
(CBP-1 [K01A2.11b]), and both of them have putative N-ter-
minal signal peptides and are therefore probably secreted.
There is one molting larval EST (SWOv3MCAM07A01SK)
corresponding to this cDNA in the current EST database.
An alignment of the deduced primary amino acid sequence
of the Ov-gmr-1 cDNA (GenBank accession number AF153721
[OVC01489]) shows extensive identities with the two known
GMP reductases from other nematodes: C. elegans (73%) and
A. suum (81%), as well as the human protein (63%). One cor-
responding EST sequence (SWOvL3CAN62B09SK) was iden-
tified in the L3 EST dataset.
(ii) Novel O. volvulus immunogenic proteins. A TBLASTX
analysis revealed that three cDNA clones isolated by immuno-
screening contained no homologues in the current public
database. The cDNA clone designated Ov-nip-1 (GenBank
accession number AF153719 [OVC00547]) encodes a highly
basic (pI 5 11.2) 32-kDa protein rich in serine, arginine, and
lysine. The N-terminal portion of the protein is predominantly
serine and arginine rich (58%) while the C-terminal region is
lysine rich (38%). Two ESTs corresponding to this cDNA
(SWOvL3CAN16C05SK and SWOv3MCA657SK) have been
identified. This protein contains four classical (29) and six
bipartite (65) nuclear localization signals. The Ov-nip-2 cDNA
(GenBank accession number AF153723 [OVC00949]) encodes
a 48-kDa protein with one potential N glycosylation site. The
cDNA has a corresponding EST (SWOv3MCA915SK) in the
mL3 EST dataset. The Ov-nip-3 cDNA (GenBank accession
number AF153722 [OVC00115]) encodes a small protein
(15 kDa) with a potential signal peptide. The cDNA has three
corresponding EST sequences in the mL3 dataset (SWOv3
MCAM07G11SK, SWOv3MCA061SK, and SWOv3MCAM11
B11SK). Based on their novelty and immunogenicity, these
proteins all represent a very attractive subset whose potentials
as vaccinogens are currently being pursued.
Antibody responses to O. volvulus recombinant proteins. Se-
rum samples from PI and INF individuals were tested against
the recombinant Ov-DLC-1, Ov-NIP-1, Ov-NIP-2, Ov-NIP-3,
and Ov-CBP-1 (Fig. 1). The mean optical density (OD) of
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three normal human serum samples plus three times the stan-
dard deviation (OD 5 0.3) determined the cut-off level. Sera
from 100% of the PI and the INF individuals recognized the
recombinant proteins. The levels of recognition by both groups
were high for all antigens (median ODs between 0.72 and
1.89). Only the response of the INF individuals to the Ov-
CBP-1 protein (OD 5 1.89) was significantly higher than in the
PI group (OD 5 1.55; P 5 0.03). Difficulties in expressing
recombinant Ov-GMR did not allow us to determine the im-
munogenicity of this protein in both groups.
DISCUSSION
The search for filarial drug targets and/or vaccine candidates
has so far been based largely on one of the following ap-
proaches: (i) immunoscreening of cDNA expression libraries
using patient sera or monoclonal antibodies, (ii) two-dimen-
sional Western blots using parasite protein extracts and
polyspecific patient sera followed by protein sequencing and
cloning, or (iii) PCR amplification of genes based on rational
(hypothesis-driven) design. With the inception of the filarial
genome projects and the vast amount of information contained
therein, an entirely new subset of genes have been identified as
possible parasite target molecules which may not have been
discovered using only the above methods. The resources of the
recently completed C. elegans genome (11) are being exploited
as a model for analysis of filarial genes, aimed at cataloging the
complete inventory of such proteins as immunogens (for vac-
cine development) and drug targets (for chemotherapy) as well
as virulence and developmental factors (21, 78). Several im-
portant genes, like transporters, receptors, proteinases, anti-
oxidants, and abundant and developmentally regulated tran-
scripts, have been identified in B. malayi and T. canis using
such a gene discovery approach (5, 25, 73). Unlike in B. malayi,
where the complete genome and gene expression profile are
being investigated, only the EST approach is being undertaken
in O. volvulus using specific life cycle stages of the parasite. In
the present study, we have employed a combination of two
strategies to identify potential vaccine candidates and drug
targets in the filarial parasite O. volvulus: analysis of 4,635 L3
and mL3 ESTs and a selective immunoscreening of the O.
volvulus mL3 cDNA library using a distinct source of human
sera. These two complementary approaches facilitated the
identification of potentially interesting genes which can be pur-
sued for development of vaccines and/or drug targets against
onchocerciasis based on their immunogenicity, up-regulation
in larval stages, and/or predicted biological features.
The EST analysis approach (Table 1) has revealed an im-
portant group of genes that are developmentally up-regulated
in L3 and/or mL3, as well as proteins that are entirely novel
and may be specific to O. volvulus and thus associated with
infection and host-parasite interactions. Other proteins have
similarity only to proteins predicted from the C. elegans ge-
nome, representing an additional group of nematode proteins
that can be more easily studied using C. elegans as a model
organism. In particular, with the availability of RNA interfer-
ence (RNAi) technology (22) the function and importance of
the C. elegans homologues for survival and/or development
could be rapidly assessed. Many of these proteins from both
groups have potential signal peptides and are thus presumably
destined for secretion, making them another attractive subset,
since ES products have been demonstrated to be valuable
candidates for vaccine development in filarial infections (32).
In the EST initiative, we have identified, among several others,
four previously uncharacterized neurotransmitter receptors,
three proteinases, two nuclear hormone receptors, and three
novel cyclophilins. Compounds such as ivermectin that inter-
rupt neurotransmission are already in use as anthelminthics,
and there is a great deal of information about their effects on
FIG. 1. Comparison of total IgG responses of the PI (n 5 21) and INF (n 5 21) individuals to recombinant Ov-DLC-1, Ov-CBP-1, Ov-NIP-1, Ov-NIP-2, and
Ov-NIP-3 proteins. Spots represent the OD of each individual serum sample, and bars represent median values in each group. The cut-off level of all the assays (broken
line) was the mean OD of three healthy human sera plus three times the standard deviation. Analysis was done by the two-tailed nonparametric Mann-Whitney U test,
and results were considered statistically significant if the P value was less than 0.05.
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nematodes and their efficacy in human infections. However,
very few of their targets have been cloned and characterized,
and the EST sequencing approach could offer interesting start-
ing points for drug development. Additionally, the presence of
homologues of O. volvulus proteins in C. elegans would allow
its use as a model organism for the development of compounds
that may interfere with the function of these proteins as ther-
apeutic targets.
The immunoscreening approach directly identified parasite
immunogens that otherwise would not have been identified as
potential vaccinogens using the EST approach. None of these
antigens would have been selected for immunological studies,
as they either are absent or have only one to three ESTs within
the datasets. In addition, some of them are conserved and/or
ubiquitous proteins, and three of them are completely novel.
Some protective novel antigens identified by immunoscreening
of L3 or adult worm cDNA libraries are also not yet repre-
sented in the EST datasets (http://helios.bto.ed.ac.uk/mbx/fgn/
OnchoNet/onchotable1.html). The ELISA data indicate that
the five antigens isolated from the mL3 cDNA library were
strongly recognized by sera from both the PI and the INF
groups (Fig. 1). As the concept of concomitant immunity has
been enunciated with regard to human filarial infections (16,
74), we propose that the comparable immune responses to-
wards the cloned antigens by the PI and INF individuals indi-
cate that these proteins may be participating in protective
responses in both groups. None of the recombinant oncho-
cerca antigens identified so far to be protective in the mouse
model were found to be uniquely recognized by the PI. The
recombinant proteins corresponding to the clones isolated by
the immunoscreening approach will have to be tested in the O.
volvulus mouse diffusion chamber model to confirm their rel-
evance in conferring protection against infection.
The strength of using the dual strategy of EST analysis and
immunoscreening is that both approaches have effectively un-
covered potential vaccine candidates and drug targets in O.
volvulus. To increase the value of our findings, additional re-
search will be required to confirm the importance of the clones
identified by the EST approach. (i) Potent inhibitors of previ-
ously characterized drug targets in other systems, whose ho-
mologues have been identified in this study, can be used to
screen for their effect on O. volvulus worms or an appropriate
model. (ii) Plaques expressing recombinant proteins that are
L3- and/or mL3-specific (based on EST analysis) can be tested
with sera from protected hosts to identify those that are im-
munogenic and therefore more associated with protective im-
munity. (iii) Extracts can be used to deplete sera in order to
preselect for antibodies directed against larva-specific anti-
gens. The depleted sera can then be used on selected cDNA
expression arrays to rapidly identify larva-specific genes and
simultaneously assess the immunogenicity of clones of interest.
Interestingly, some of the highly expressed stage-specific
and/or up-regulated genes in the L3 library have already been
shown to be antigenic (ALT, ASP, CPI-2) (39, 47, 70). (iv)
Plaque cellular proliferation assays can also be performed us-
ing arrays of such genes designed to select those that are able
to induce particular cytokine responses in PI versus INF indi-
viduals. (v) Selected genes could be subcloned into mammalian
expression vectors and then used for DNA immunization in the
O. volvulus mouse diffusion chamber model (45). The combi-
nation of molecular and immunological approaches has thus
provided us with tools that will be used in our continuing effort
to elucidate a proactive method of combating onchocerciasis.
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